unknown
Stage
About
DCxBio develops next-generation precision multi-modal antibody drug conjugates using an integrated CRISPR, bioinformatics, and machine learning platform to target cancer at its cellular roots by identifying lesion-specific targets for improved therapeutic responses.
Explore DCxBio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.